Introduction
Thyroid cancer is the most commonly diagnosed type of head and neck cancer (1) . Differentiated thyroid cancer is the most common type of thyroid cancer, which accounts for >95% of all cases (2) . Due to increased use of diagnostic imaging and surveillance techniques over the last 30 years, with the exception of Africa, the incidence rates of thyroid cancer have continued to increase worldwide, and it accounted for 3.4% of all cancers in the USA in 2017 (3, 4) . The B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) V600E mutation is one of the most common mutations observed in thyroid cancer.
Keratins are the intermediate filament (IF)-forming proteins in epithelial cells and have been long and extensively used as immunohistochemical markers for the pathological diagnosis of tumors (5) . The keratin 19 (KRT19) gene, located at chromosome17q21.2, encodes for the cytokeratin (CK)19 protein, CK-19, which is an acidic protein type I CK (6) . KRT19 has been studied as a prognostic marker and has been found to exert specific biological roles in numerous types of cancer, including hepatocellular carcinoma, pancreatic neuroendocrine tumors and potentially HER2-positive breast cancer (7) (8) (9) (10) . However, its role in thyroid cancer is currently unclear, therefore, the aim of the present study was to examine the role of KRT19 in thyroid cancer cell lines, and further explore the potential mechanism of KRT19 overexpression. KRT19 expression was observed to be higher in thyroid cancer samples when compared with normal thyroid tissue samples and therefore, may function as a potential oncogene that promotes thyroid cancer cell proliferation and migration in vitro. In addition, the present study, to the best of our knowledge, reported for the first time that the BRAF V600E mutation may contribute to the oncogenic function of KRT19. This suggests that KRT19 and BRAF V600E may serve a role in epithelial-mesenchymal transition (EMT).
Materials and methods
Data sources. The Cancer Genome Atlas (TCGA), Level 3 thyroid cancer data were first downloaded from UCSC Xena (https://xenabrowser.net/datapages/). The TCGA Thyroid Cancer (TCGA_THCA) dataset (ID, TCGA.THCA. sampleMap/HiSeqV2; version 20171013) contained the following information on 572 patients with thyroid cancer: Tumor-Node-Metastasis (TNM) stage (11) , age, grading, pathology type (follicular subtype, classical subtype and tall cell subtype) and other clinical parameters. The TCGA_ THCA dataset was produced using Illumina HiSeq (Illumina, Inc.), consisted of 59 normal thyroid tissues and 505 cancer tissues, and was analyzed using the unit log 2 (count+1), and 'count' was considered as the second-generation sequencing RSEM normalized count (12 RNA preparation and RT-qPCR. Total RNA was extracted from cultured 8505C and BHT101 cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). For reverse transcription, 1,000 ng total RNA was reverse transcribed to produce a final volume of 20 µl cDNA using a Reverse Transcription kit (cat. no. RR036A; Takara Biotechnology, Co., Ltd.), according to the manufacturer's protocols. RT-qPCR analyses were performed using SYBR Select Master Mix (cat. no. 4472908; Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. The RT-qPCR primers for KRT19 were as follows: Forward, 5'-AAC GGC GAG CTA GAG GTG A-3', and reverse, 5'-GGA TGG TCG TGT AGT AGT GGC-3', the primers for BRAF WT /BRAF V600E were forward, 5'-AAT ACA CCA GCA AGC TAG ATGC-3', and reverse, 5'-AAT CAG TTC CGT TCC CCA GAG-3'. β-actin was used as the reference gene with the following primer sequences: Forward, 5'-CAT GTA CGT TGC TAT CCA GGC-3' and reverse, 5'-CTC CTT AAT GTC ACG CAC GAT-3'. RT-qPCR data was collected using the QuantStudio™ 6 Flex Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) and RT-qPCR thermocycling conditions consisted of an initial denaturation step at 95˚C for 10 min, followed by 40 cycles of 92˚C for 15 sec and 60˚C for 1 min. Each sample was run in triplicate and the relative expression of the target gene was calculated and normalized relative to β-actin using the 2 -ΔΔCq method (16) Protein preparation and western blot analysis. Whole cells were lysed on ice with RIPA buffer (cat. no. P0013; Beyotime Institute of Biotechnology), and a bicinchoninic acid assay kit was used to quantify the protein concentration. Equal quantities (15 µg) of protein were loaded onto 12% SDS PAGE gels. Following separation, protein samples were transferred to nitrocellulose membranes. The membranes were blocked in 2% bovine serum albumin (cat. no. A4737; Sigma-Aldrich; Merck KGaA) in Tris-buffered saline and Tween 20 (TBST) for 1 h at room temperature and incubated with antibodies at 4˚C overnight. The membranes were then washed in TBST and incubated with HRP-coupled secondary antibodies for 2 h at room temperature. After that membranes were treated with enhanced chemiluminescence western blotting substrate (Pierce; cat. no., 32106) at room temperature for 1 min, X-ray films (CL-XPosure™ Film; cat. no. 34090, Thermo Fisher Scientific, Inc.) were used for detecting the blots. All experiments were repeated in triplicate and the antibodies are presented in Table I .
Cell proliferation and migration assays. The Cell Counting Kit-8 (CCK8; cat. no. CK04; Dojindo Molecular Technologies, Inc.) was used to determine the cell proliferation rate. Cells were seeded in 96-well plates at a density of 2,000 cells/well (100 µl total volume), and the absorbance was measured at a wavelength of 450 nm using an ELx800 Universal Microplate Reader (Norgen Biotek Corp.), according to the manufacturer's protocols. Each experiment was repeated in quadruplicate at 0, 24, 48, 72 and 96 h.
For migration assays, transfected cells (40,000 cells/well; 100 µl total volume) were seeded in the upper chamber of Transwell assay inserts (8-mm pores; EMD Millipore) containing 200 µl serum-free media. The lower chambers were filled with media containing 10% FBS. Following incubation for 24 h, cells on the filter surface were fixed with 90% methanol (-20˚C) for 10 min and then stained with crystal violet for 10 min at room temperature. Images were captured using a light inverted microscope (magnification, x40; Axio Observer; Carl Zeiss AG) and cell migration was assessed by counting the number of stained cells in five random fields of view/filter for each group. Experiments were repeated in triplicate. software were used for statistical analyses and the production of graphs. Data are presented as the mean ± standard deviation, and were analyzed using a Student's t-test, and one-way analysis of variance with Tukey's multiple comparisons post-hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results

KRT19 expression is increased in thyroid cancer tissues and is associated with more aggressive clinical characteristics.
The TCGA thyroid cancer dataset was downloaded and used for the purposes of this study. As demonstrated in Fig. 1A , the expression profile of genes in the thyroid cancer dataset are presented as a volcano plot (cancer vs. normal), and KRT19 was observed to be at an upregulated position. As demonstrated in Fig. 1B , KRT19 expression was significantly higher in tumor samples when compared with adjacent normal samples (P<0.001). In addition, KRT19 expression was associated with lymph node metastasis and significantly higher expression levels were observed in the lymph node positive group (P<0.001; Fig. 1C ). When patients were categorized by pathological subtype, the follicular subtype (best prognosis) group exhibited the lowest KRT19 expression levels, while the tall cell subtype (worst prognosis) group exhibited the highest KRT19 expression levels (follicular subtype vs. classical subtype, P<0.0001; follicular subtype vs. tall cell subtype, P<0.0001; and classical subtype vs. tall cell subtype, P=0.0013; Fig. 1D ). Patients in the TNM stage III-IV group exhibited significantly higher KRT19 expression levels when compared with those in the TNM stage I-II group (P<0.001; Fig. 1F ). Similar results were observed for tumor stage analysis (P<0.001; Fig. 1E ; Table II) .
KRT19-knockdown inhibits thyroid cancer cell proliferation and migration, however, not apoptosis in vitro.
To investigate the role of KRT19 in thyroid cancer cell lines the siRNA knockdown system was used. Using two different thyroid cancer cell lines, 8505C and BHT101, the efficiency of siRNA-knockdown was measured by RT-qPCR and western blot analyses ( Fig. 2A and B) . Using Transwell assays, the migration ability of 8505C cells was also measured. As demonstrated in Fig. 2C , the migration ability of 8505C cells was significantly reduced following knockdown of KRT19 (P<0.001). The proliferation of thyroid cancer cell lines was then analyzed using a CCK8 assay and fluorescence-activated cell sorting (FACS) in both cell lines. As presented in Fig. 2D , the negative control (NC) groups demonstrated higher cell counts, and the results of FACS analysis indicated no significant alterations in the apoptosis rate between the NC and the si-KRT19 group (Fig. 2E) . These results suggest that knockdown of KRT19 decreased the proliferation ability of thyroid cancer cells.
Increased KRT19 expression may be induced by the BRAF V600E
mutation. In the TCGA thyroid cancer dataset, it was observed that compared with normal group, the expression of KRT19 was higher only in the BRAF V600E group, however, not the WT group (Fig. 3A) . Therefore, BRAF V600E and BRAF WT sequences were then overexpressed in 8505C cells. qRT-PCR results indicated these plasmids could significantly upregulate the expression of BRAF WT or BRAF V600E ( Fig. 3B and C) . As demonstrated in Fig. 3D and E, the mutation group exhibited higher expression levels of KRT19 when compared with WT group. The results demonstrated that high expression levels of KRT19 were only observed in patients harboring the BRAF V600E mutation, which suggests that BRAF V600E may induce KRT19 expression. 
KRT19 exerts its oncogenic activity via EMT.
To further investigate the role of KRT19 and the BRAF V600E mutation in thyroid cancer, GSEA was used. Patients from the TCGA thyroid cancer dataset were grouped according to BRAF mutation status (BRAF V600E and WT BRAF groups), and the expression profiles for each group were submitted for GSEA analysis. The results indicated that the BRAF mutation status was significantly associated with EMT ( Fig. 4A and D) . As demonstrated in Fig. 4B and C , GSEA was used to analyze the gene expression profiles of the top 10 tumor samples exhibiting the highest levels of KRT19 expression and the top 10 tumor samples exhibiting the lowest expression of KRT19, which revealed EMT. These results suggest that KRT19 may influence EMT. Therefore, the expression of EMT markers was analyzed in 8505C cells, and the results demonstrated that the level of E-cadherin was significantly higher in cells transfected with si-KRT19, whereas N-cadherin expression levels were significantly lower when compared with the controls.
Discussion
KRT19 is a member of the keratin family of IF proteins, which can be further subdivided into CKs and hair keratins (17) . KRT19, as a type I CK, has been reported to be abundantly expressed in epithelial tumor cells and serves as a marker for metastatic tumors (18) (19) (20) . A previous study suggested that KRT19 expression may be activated by certain signaling pathways. For example, Ju et al (10) reported that the erb-b2 receptor tyrosine kinase-2 (ERBB2/HER2)-downstream MEK/ERK signaling pathway stimulated KRT19 expression, and membrane-localized KRT19 can bind to and stabilize HER2 by inhibiting its ubiquitination. In thyroid cancer, increased KRT19 expression was observed in papillary carcinoma when compared with follicular adenoma (21) . However, the role of KRT19 in thyroid cancer is currently unclear, so in order to clarify the phonotype of KRT19 in thyroid cancer cell lines and examine its downstream mechanism the present study designed and performed the aforementioned experiments.
The current study presents evidence to suggest that KRT19 expression is elevated in thyroid cancer, which is associated with lymph node metastasis, increased tumor size and advanced TNM stage. Using CCK8 assays and apoptosis analysis, KRT19 knockdown was demonstrated to reduce the proliferation of thyroid cancer cells; however, this was not via the induction of apoptosis. In agreement with the observation that KRT19 was associated with lymph node metastasis, the results of the Transwell assay indicated that KRT19-knockdown decreased the migration of thyroid cancer cells. BRAF V600E is the most frequently mutated gene in thyroid cancer and, according to the cBioPortal, this mutation is present in ~60% of all cases (22) . Therefore, the association between BRAF V600E and KRT19 expression was investigated in the current study. Notably, the expression of KRT19 was observed to be significantly higher in BRAF V600E tumors compared with WT tumors. By transfecting thyroid tumor cells with a plasmid containing BRAF V600E , this mutation was observed to induce the expression of KRT19. Therefore, to the best of our knowledge, this is the first study to report that increased KRT19 expression could be caused by BRAF V600E mutations. Consistent with this hypothesis, GSEA analysis of BRAF V600E vs. WT BRAF thyroid cancer samples indicated EMT. In addition, KRT19 expression was associated with lymph node metastasis in thyroid cancer patients, and GSEA analysis yielded similar results. KRT19 is also known to be involved in EMT (8) . Therefore, the level of specific EMT makers were measured in thyroid cancer cell lines in the present study. E-cadherin levels were increased while N-cadherin levels were decreased in thyroid cancer cells transfected with si-KRT19, which indicated that knockdown of KRT19 may influence EMT.
In conclusion, the results of the current study suggest that BRAF V600E mutations may increase the expression of KRT19 in thyroid cancer, which may subsequently lead to lymph node metastasis via induction of EMT.
